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Despite almost a decade of intense research, effective treatment strategies for Patholog-
ical Gambling (PG) remain very challenging. This paper details a case report suggesting
that the treatment of PG may benefit from the use of the non-specific glutamate blocker
amantadine. The drug was well-tolerated and effective, leading to a 43–64% reduction in
severity of gambling symptoms (as measured with G-SAS). Our result is discussed in the
context of the glutamatergic hypothesis of addiction and in light of previous observations
on the potential impact of glutamatergic agents in the treatment of PG. The role of the
dopaminergic system, and its interaction with the glutamatergic system, is also explored.
Further studies are required to define the true benefits of amantadine for the treatment
of PG.
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BACKGROUND
Pathological gambling (PG) is characterized by persistent and
maladaptive gambling behavior, whereby individuals engage in
frequent and repeated episodes of gambling despite serious adverse
consequences (Hodgins et al., 2011). Gambling disorder affects
0.2–5.3% of adults worldwide; the devastating consequences of
this behavioral disturbance often entail severe damage to the lives
of patients and their families. To date, there is no FDA-approved
treatment for PG, despite almost a decade of intense research, and
effective treatment strategies remain very challenging.
Recently, it has been proposed that PG be included in the diag-
nostic category of Substance Use and Addictive Disorders of the
next edition of the Diagnostic and Statistical Manual of Mental
Disorders (DSM-V; Petry, 2010). The clinical and biological sim-
ilarities between PG and drug addiction (Potenza, 2008) suggest
that PG patients may benefit from medication used to treat drug
addiction and that pathophysiological models for drug addiction
may be relevant to PG as well. It has been recently proposed that
addiction be viewed as the result of an impaired ability to inhibit
drug seeking in response to environmental contingencies, due to
alterations in glutamate (Glu) homeostasis, with combined acti-
vation of sensitized dopamine (DA) and N -methyl-d-aspartate
(NMDA) glutamatergic receptors (Kalivas, 2009).
Pathological Gambling has been presumed to be modulated
mainly by brain DA and Glu, though findings are contrasting. DA
is implicated in rewarding, reinforcing, and addictive behaviors.
In drug addiction, data support the existence of a hypodopamin-
ergic state at both the presynaptic and postsynaptic levels (Melis
et al., 2005). Alterations in dopaminergic pathways may underlie
the seeking of rewards (i.e., gambling) that trigger DA release and
produce feelings of pleasure. While the acute rewarding effects
of addictive behaviors seem to be mediated by enhanced DA
transmission and DA release may reinforce reward learning, Glu
may be implicated in long-lasting neuroadaptations in the corti-
costriatal circuitry, that represents the putative neural substrate
of enduring vulnerability to relapse (Kalivas, 2009). The imbal-
ance in Glu homeostasis engenders changes in neuroplasticity
that impair communication between the prefrontal cortex and the
nucleus accumbens, thus favoring engagement in reward-seeking
behaviors, such as PG (Kalivas and Volkow, 2011).
Amantadine is an antiglutamatergic drug with NMDA receptor
antagonistic properties. Amantadine also has additional actions
on dopaminergic neurotransmission; it increases DA release,
has direct effects on DA receptors, and inhibits DA reuptake
(Stromberg et al., 1970). Amantadine was originally approved as
an antiviral agent (Davies et al., 1964) as it inhibits influenza A
virus replication. With its pro-dopaminergic actions, amantadine
was later approved for Parkinson’s disease (PD) and for drug-
induced parkinsonism (Schwab et al., 1969). It continues to be a
widely used and well-tolerated drug in the treatment of parkinson-
ian movement disorders and may also slow the progression of PD
(Blanchet et al., 2003), ameliorate chronic pain (Fisher et al., 2000),
and improve recovery from traumatic brain injury (Meythaler
et al., 2002). Pro-dopaminergic actions and NMDA antagonistic
actions are suggestive of amantadine’s possible efficacy for depres-
sion. The adverse effects of amantadine are generally mild. The
most commonly reported side effects include nausea, dizziness,
and insomnia. Confusion, ataxia, headache, agitation, and fatigue
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have been reported, but are less frequent. Psychiatric side effects
include depression, anxiety, irritability, and dream abnormality.
Psychosis, euphoria, and amnesia have also been reported. Sui-
cidal ideation, aggressive behavior, delirium, delusions, paranoid
reactions, and impulse control symptoms have been reported, but
are rare.
Based on amantadine’s properties of stimulating DA release,
several studies on its use in cocaine addiction have been conducted,
though findings are contrasting. In cocaine-dependent patients
with severe withdrawal symptoms, Kampman et al. (2000) found
that amantadine was effective. Two double-blind trials yielded
similar results (Alterman et al., 1992; Shoptaw et al., 2002). How-
ever, several other placebo-controlled trials have not confirmed
amantadine’s effectiveness in cocaine dependence (Giannini et al.,
1989; Weddington et al., 1991; Kampman et al., 2006). Aman-
tadine has also been reported to be effective in reducing PG in
patients with PD (Thomas et al., 2010). In the latter study, aman-
tadine resolved PG in seven patients after 4 days of treatment;
conversely, amantadine withdrawal may have been associated with
the reappearance of the disorder. Although not previously stud-
ied in PG, we hypothesized that, on the basis of these findings,
and on its potential to interact with Glu homeostasis and DA
function, amantadine would reduce gambling craving as well as
gambling behavior. In this report, we present the first experience
using amantadine to treat PG.
CASE PRESENTATION
The present case concerned a 47-year-old married male, unem-
ployed, previously diagnosed with PG (about 10 years ago). He
first started engaging in problematic gambling at horse betting
and slot machines 25 years ago. Though he has no criminal his-
tory, he has run up about 20,000 euros in debts due to PG. The
patient also reported a history of opioid dependence, in remission
for 12 years.
At intake assessment, the patient met DSM-IV-TR (American
Psychiatric Association, 2000) and ICD-10 criteria for PG, and
was currently experiencing a Major Depressive Episode (MDE)
according to DSM-IV-TR. He also met criteria for alcohol depen-
dence, nicotine dependence, and occasional cocaine abuse. The
patient did not receive psychological or pharmacological treat-
ments for the opioid and alcohol dependence. Personality traits
were explored using the Temperament and Character Inventory –
Revised (TCI-R; Cloninger et al., 1993; Martinotti et al., 2008):
he reported low scores on Harm Avoidance, Persistency, Self-
Transcendence, and high scores on Cooperativeness. Impulsivity
was measured with the Barratt Impulsiveness Scale, Version 11
(BIS-11; Patton et al., 1995), and a score of 73 was obtained, indi-
cating high levels of impulsivity. The Hamilton Depression Rating
Scale (HAM-D, Hamilton, 1960) and the Young Mania Rating
Scale (YMRS; Young et al., 1978) were also administered in order
to assess mood symptoms; a score of 17 was obtained on the HAM-
D and a score of 2 was obtained on the YMRS. Gambling craving
was assessed with the Gambling Symptom Assessment Scale (G-
SAS; Kim et al., 2009) and a score of 44 was obtained, which
reflects extreme severity of the gambling urge. The patient was
initially assigned to a semi-residential treatment program at the
Day Hospital of Psychiatry of the Catholic University in Rome,
during which he received antidepressant medication (escitalopram
20 mg/day) and joined rehabilitation groups (two sessions per
week) specifically aimed at managing PG and raising illness aware-
ness. Alcohol withdrawal symptoms were treated with pregabalin
(225 mg/day) and sleep disturbance with trazodone (50 mg/day).
After 4 weeks of treatment, though the depressive condition had
improved significantly (total score HAM-D= 2), he continued to
gamble and no change was reported in gambling craving scores,
as measured with the G-SAS. Three months after the first assess-
ment, he was referred to the psychiatric ward of the clinic “Villa
Maria Pia” in Rome. Upon admission, he did not present acute
psychopathological conditions, with the exception of alcohol and
gambling craving. Treatment with amantadine was initiated, after
the patient gave his written informed consent. The study consisted
of 10 weeks of open-label amantadine. Amantadine was adminis-
tered with a titration schedule of 50 mg daily for 1 week, 50 mg
twice daily (bid) for 2 weeks, and 100 mg+ 50 mg for the rest of
the study period. During all the study period, the patient con-
tinued to receive the previous treatment (pregabalin 225 mg/day;
trazodone 50 mg/day) to treat alcohol withdrawal symptoms (Di
Nicola et al., 2010). At baseline, G-SAS was administered and
the subject reported the previous score of 44. Depressive and
manic/hypomanic symptoms were assessed using the HAM-D
and the YMRS (see Table 1). HAM-D, YMRS, and G-SAS were
repeated after 2, 4, and 8 weeks. After the first 2 weeks of treat-
ment the patient was discharged from the clinic and continued
receiving amantadine as an outpatient at the Day Hospital of Psy-
chiatry of the Catholic University in Rome. Safety assessment at
each visit included evaluation of sitting blood pressure, heart rate,
and weight. The patient tolerated the medication well, without
any side effects. ECG results were normal throughout the entire
study period, and no effect on QTc interval was observed. Also,
the patient did not report any significant anticholinergic side
effects. During the study period, the patient reported a reduc-
tion of 43–64% in G-SAS scores (with a reduction from extreme
to mild-moderate gambling urge; Figure 1), no change in mood
assessment was observed, and only one relapse in PG behaviors
was reported.
DISCUSSION
To our knowledge, this is the first case report examining the effi-
cacy of amantadine in treating PG patients, without comorbid
Table 1 | Changes in study measures of the patient with pathological
gambling treated with amantadine.
Baseline 2weeks* 4weeks* 8weeks*
G-SAS 44 16 22 25
HAM-D 2 3 6 5
YMRS 5 3 4 3
Gambling relapse (n/days) 18/30 0/14 1/14 0/30
Alcohol TLFB 5/30 0/14 2/14 3/30
G-SAS, Gambling Symptom Assessment Scales; HAM-D, Hamilton Depression
Rating Scale; TLFB, Alcohol Timeline Follow Back; YMRS, Young Mania Rating
Scale. *After administration of amantadine.
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FIGURE 1 | Results of Gambling SymptomsAssessment Scale (G-SAS), at baseline and follow up.
PD. We found that PG symptoms improved significantly during
the study period. This suggests that simultaneous pharmacolog-
ical modulation of the glutamatergic and dopaminergic systems
may reduce gambling in PG.
Amantadine is an old drug, but new potential uses were only
recently discovered (Rajput et al., 1998; Hubsher et al., 2012).
Besides its established use in the treatment of levodopa-induced
dyskinesia (Pappa et al., 2010; Sawada et al., 2010), amantadine has
also recently been studied in PD patients as an additional treat-
ment option for punding (a stereotyped behavior characterized
by intense fascination with complex, excessive, non-goal-oriented,
repetitive activities; Fasano et al., 2011) and PG (Thomas et al.,
2010), in light of the hypothesis that both dyskinesias and com-
pulsive behaviors (such as PG and punding) represent part of
a pathological continuum secondary to abnormal dopaminergic
stimulation in the basal ganglia (Voon et al., 2009).
There is substantial evidence indicating that pharmacological
treatments targeting glutamatergic transmission are of potential
utility in the treatment of drug addiction. Given that neuro-
biological findings indicate that PG and drug addiction share
common etiopathological pathways (Potenza, 2008), drugs target-
ing glutamatergic transmission could be of use for the treatment
of behavioral addictions (i.e., PG) as well (Kalivas, 2009; Olive
et al., 2012). Previous glutamatergic treatment strategies for PG
proved to reduce gambling urges and behavior. A small clinical
trial showed that N -acetylcysteine, an amino acid that seems to
restore extracellular Glu concentration in the nucleus accumbens,
lowered scores on the Yale Brown Obsessive Compulsive Scale
adapted for PG (PG-YBOCS; Grant et al., 2007). In line with this
finding, a subsequent open-label study reported that memantine, a
non-competitive antagonist at the NMDA receptor, decreased PG-
YBOCS scores and time spent gambling (Grant et al., 2010), also
improving neurocognitive function related to cognitive flexibility.
The dopaminergic system has also been targeted, for the treat-
ment of both drug and behavioral addictions (Diana, 2011). Neu-
roimaging research suggests that the dopaminergic mesolimbic
pathway from the ventral tegmental area to the nucleus accumbens
might be involved in PG. Pathological gamblers have diminished
ventral striatum, ventromedial prefrontal cortex, and ventrolat-
eral prefrontal cortex activity during rewarding events, suggesting
that there is a blunted neurophysiological response to rewards
and losses (Reuter et al., 2005; de Ruiter et al., 2009). To date,
treatment strategies in PG patients based on dopaminergic sys-
tem manipulation have proven to be ineffective. Bupropion, a
DA and noradrenaline reuptake inhibitor, showed no benefit over
placebo (Black et al., 2007). Antagonists at dopamine D2/D3 recep-
tors enhanced gambling-related motivation and behaviors in PG
patients (Zack and Poulos, 2007). In pathological gamblers, multi-
ple investigations have observed alterations in frontal regions and
in the ventral striatum (nucleus accumbens), a brain region with
dopaminergic innervation widely implicated in reward processing
(Everitt and Robbins, 2005). It has been hypothesized that two
mechanisms of midbrain and striatal dopaminergic projections
may be involved in PG: hypersensitivity to reward and sustained
activation toward uncertainty (Linnet et al., 2012). Furthermore,
Joutsa et al. (2012) suggested that the dopaminergic response to
reward-predicting stimuli and the link between addiction severity
and DA release in pathological gamblers may be relevant to the
onset and course of PG. As an indirect DA agonist, amantadine
may be able to stimulate the release of DA and potentially restore
the physiological activity of the DA system, yielding significant
clinical improvements in PG patients (reduction of craving and
relapse).
Amantadine may act as a regulator of the complex interac-
tions between the glutamatergic and dopaminergic systems, acting
simultaneously on both systems, in ways that need to be better
explored. Takahashi et al. (1996) proposed that amantadine may
stimulate D2 receptors distributed in Glu nerve terminals, thereby
enhancing Glu release in the striatum. Enhanced Glu transmission,
in turn, would induce a further increase in DA through NMDA
receptors located in DA nerve terminals. Intriguing hypotheses
can be formulated in light of the recent discovery of the existence
of a co-release of Glu and DA in reward-related areas. Based on
the finding of VGLUT2 expression in DA neurons of brain regions
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projecting to the nucleus accumbens and on electrophysiological
recordings showing glutamatergic transmission in mesoaccumbal
slice preparations (Chuhma et al., 2004), it has been suggested
that VGLUT2-mediated Glu co-transmission might have a role
in reward-relevant pathways (El Mestikawy et al., 2011). Further
studies are needed to better understand the action of amantadine
on neural systems involved in PG.
CONCLUDING REMARKS
Our data seem to confirm the utility of targeting the Glu system
for the treatment of PG, and suggest that the non-specific Glu
blocker amantadine may possibly be a viable treatment option.
Since amantadine presumably modulates Glu homeostasis, we
hypothesize that its therapeutic action is linked to the restoration
of prefrontal projections to the ventral striatum (nucleus accum-
bens), thus reversing neuroplasticity-based pathological changes
putatively determined by addictive behaviors (Kalivas, 2009).
Though the use of amantadine in the treatment of PG appears
to be promising, further studies are certainly needed. Consid-
ering that this is the only case report describing such a new
therapeutic use for amantadine, the generalizability of the effi-
cacy results is limited. Future investigations would benefit from
placebo-controlled clinical trials to further outline the true bene-
fits of amantadine for the treatment of PG. Future studies should
also focus on the functional connections between dopaminergic
and glutamatergic systems, in order to shed light upon the com-
plex neurobiological mechanisms underlying the development of
maladaptive gambling behavior.
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